Aeon Biopharma (AEON) said Friday it received a notice from NYSE American stating it is not in compliance with the stockholders' equity requirement, which requires at least $2 million in equity.
The company reported a stockholders' deficit of $32.1 million as of Sept. 30 and has incurred losses from continued operations in two of its most recent fiscal years.
Aeon said it has until March 5 to submit a plan to regain compliance and intends to do so
Shares of Aeon Biopharma were down more than 7% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.